LUNGevity Foundation
Her clinical practice focuses primarily on the care of patients with lung cancer. Her laboratory research focuses on understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer. She is also co-editor-in-chief for the website www.mycancergenome.org, a Vanderbilt-initiated freely available website that aims to provide healthcare practitioners, patients, and advocates with up-to-date information on genetically informed cancer medicine.
Dr. Lovly received a BA in chemistry from Johns Hopkins University followed by MD and PhD degrees as part of the Medical Scientist Training Program at Washington University in St. Louis, MO. She then completed internal medicine residency and medical oncology subspecialty training at Vanderbilt University. During her final year of fellowship, she was the Jim and Carol O'Hare Chief Fellow. She started on faculty at Vanderbilt in July 2013.
Dr. Lovly has received grant funding from NIH/NCI, Uniting Against Lung Cancer, the Conquer Cancer Foundation of the American Society of Clinical Oncology, the Sarcoma Foundation of America, the American Cancer Society, the Damon Runyon foundation, LUNGevity Foundation, the V Foundation, the American Association for Cancer Research, and Lung Cancer Foundation of America / International Association for the Study of Lung Cancer. She is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR). Dr. Lovly is also an elected member of the American Society for Clinical Investigation (ASCI) and serves on the Editorial Board for Cancer Discovery.
This person is not in the org chart
This person is not in any offices
LUNGevity Foundation
2 followers
LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, policy initiatives, education, support, and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease—while promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivors—and those who help them live longer and better lives.